JCR Pharmaceuticals launches Phase III trial for JR-142 in Japan, a long-lasting growth hormone treatment.

Merck signs exclusive global licensing deal for LM-299, a candidate bispecific antibody targeting PD-1 and VEGF.

InflaRx reports the initial patient has been treated in the Phase 2a trial for the oral C5aR inhibitor INF904.

Novo Nordisk A/S: In the REDEFINE 1 trial, CagriSema shows better weight loss results for adults with obesity or excess weight.

Oruka Therapeutics reports that the initial participants have received doses in the Phase 1 trial of ORKA-001, a new antibody that extends half-life and targets IL-23p19.

Regeneron will move forward with two Factor XI antibodies into an extensive Phase 3 program after successful Phase 2 proof-of-concept outcomes.

Vittoria Biotherapeutics has commenced dosing the initial patient in the Phase 1 clinical trial for VIPER-101.

TRYNGOLZA™ (olezarsen) has received U.S. approval as the first treatment for adults with familial chylomicronemia syndrome, used alongside dietary changes.

Vertex Reports Outcomes from Phase 2 Trial of Suzetrigine for Painful Lumbar Radiculopathy Treatment.

Adicet Bio has reported the dosing of the initial patient in a Phase 1 clinical trial for ADI-270 targeting metastatic/advanced clear cell renal cell carcinoma.

Omeros' Narsoplimab Achieves Key Trial Goal – Data Analysis Reveals Better Survival Compared to External Control in TA-TMA Patients.

Sorriso Pharmaceuticals Reveals Favorable Phase 1b Trial Results for SOR102 in Treating Ulcerative Colitis.